PE20211382A1 - Piridazinonas como inhibidoras de parp7 - Google Patents

Piridazinonas como inhibidoras de parp7

Info

Publication number
PE20211382A1
PE20211382A1 PE2020001749A PE2020001749A PE20211382A1 PE 20211382 A1 PE20211382 A1 PE 20211382A1 PE 2020001749 A PE2020001749 A PE 2020001749A PE 2020001749 A PE2020001749 A PE 2020001749A PE 20211382 A1 PE20211382 A1 PE 20211382A1
Authority
PE
Peru
Prior art keywords
pyridazinones
parp7
inhibitors
dihydropyridazin
acetylpiperidin
Prior art date
Application number
PE2020001749A
Other languages
English (en)
Inventor
Melissa Marie Vasbinder
Laurie B Schenkel
Kerren Kalai Swinger
Kevin Wayne Kuntz
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of PE20211382A1 publication Critical patent/PE20211382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta referido a derivados de piridazinona de Formula I, en donde: X es Cl, Br, CH3, CF3, CN, OCH3, etilo, ciclopropilo, SCH3, o isopropilo; A es una de las formulas: (A-1), (A-2), y (A-3). Entre los compuestos preferidos tenemos los siguientes: 5-[5-[(1-acetilpiperidin-4-il)oxi]-6-fluoro-2,3-dihidro-1 H-isoindol-2-il]-4-(trifluorometil)-2,3-dihidropiridazin-3-ona; 5-[6-[(1-acetilpiperidin-4-il)oxi]-4-fluoro-2,3-dihidro-1H-isoindol-2-il]-4-(trifluorometil)-2,3-dihidropiridazin-3-ona; entre otros. Estos compuestos son inhibidores de PARP7 y son utiles en el tratamiento de cancer.
PE2020001749A 2018-04-30 2019-04-29 Piridazinonas como inhibidoras de parp7 PE20211382A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30
PCT/US2019/029582 WO2019212937A1 (en) 2018-04-30 2019-04-29 Pyridazinones as parp7 inhibitors

Publications (1)

Publication Number Publication Date
PE20211382A1 true PE20211382A1 (es) 2021-07-27

Family

ID=66476851

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001749A PE20211382A1 (es) 2018-04-30 2019-04-29 Piridazinonas como inhibidoras de parp7

Country Status (34)

Country Link
US (5) US10550105B2 (es)
EP (2) EP3788040B1 (es)
JP (2) JP6942896B2 (es)
KR (1) KR20210014108A (es)
CN (1) CN112424188A (es)
AR (1) AR121419A1 (es)
AU (2) AU2019262927B2 (es)
BR (1) BR112020022006A2 (es)
CA (1) CA3098585A1 (es)
CL (1) CL2020002821A1 (es)
CO (1) CO2020013599A2 (es)
CR (1) CR20200518A (es)
CY (1) CY1126132T1 (es)
DK (1) DK3788040T3 (es)
EA (1) EA202092590A1 (es)
EC (1) ECSP20069404A (es)
ES (1) ES2949538T3 (es)
FI (1) FI3788040T3 (es)
HR (1) HRP20230458T1 (es)
HU (1) HUE062096T2 (es)
IL (2) IL278116B2 (es)
LT (1) LT3788040T (es)
MA (1) MA52486B1 (es)
MD (1) MD3788040T2 (es)
MX (2) MX2020011465A (es)
PE (1) PE20211382A1 (es)
PH (1) PH12020551760A1 (es)
PL (1) PL3788040T3 (es)
PT (1) PT3788040T (es)
RS (1) RS64283B1 (es)
SG (1) SG11202010183XA (es)
SI (1) SI3788040T1 (es)
TW (2) TWI811353B (es)
WO (1) WO2019212937A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202010183XA (en) * 2018-04-30 2020-11-27 Ribon Therapeutics Inc Pyridazinones as parp7 inhibitors
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
US11512090B2 (en) 2018-06-11 2022-11-29 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
EP4041770A4 (en) * 2019-10-07 2023-11-08 Pipeline Therapeutics, Inc. MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
AU2020375821A1 (en) * 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
CA3186684A1 (en) * 2020-06-09 2021-12-16 Relive Therapeutics Inc. Compounds comprising a three ring core as pd-1/pd-l1 blockers
WO2022001767A1 (zh) * 2020-07-03 2022-01-06 武汉朗来科技发展有限公司 一种杂环化合物及其应用
CN116157396A (zh) * 2020-11-27 2023-05-23 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
WO2022166749A1 (zh) * 2021-02-03 2022-08-11 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
WO2022166817A1 (zh) * 2021-02-07 2022-08-11 武汉朗来科技发展有限公司 一种杂环化合物、其中间体、其制备方法及其应用
EP4291560A1 (en) * 2021-02-09 2023-12-20 Jacobio Pharmaceuticals Co., Ltd. Tricyclic derivatives useful as parp7 inhibitors
JP2024506684A (ja) * 2021-02-16 2024-02-14 ライボン・セラピューティクス・インコーポレイテッド Ｐａｒｐ７阻害物質の投与レジメン
CN115028648A (zh) * 2021-03-03 2022-09-09 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
KR20230171440A (ko) 2021-03-31 2023-12-20 듀크 스트리트 바이오 리미티드 약학적 화합물
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2022242750A1 (zh) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用
CN117396485A (zh) * 2021-05-25 2024-01-12 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
WO2023001296A1 (zh) * 2021-07-23 2023-01-26 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CN117377665A (zh) * 2021-08-16 2024-01-09 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
CN115745971A (zh) * 2021-12-20 2023-03-07 重庆华森制药股份有限公司 Parp7抑制剂及其应用
CN116375688A (zh) * 2021-12-23 2023-07-04 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CN116535395A (zh) * 2022-01-26 2023-08-04 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CA3220874A1 (en) * 2022-04-01 2023-10-05 Bing Li Parp7 inhibitor and use thereof
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
WO2024032410A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途
WO2024032409A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物在联合放疗治疗肿瘤中的用途
WO2024037558A1 (en) * 2022-08-17 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. Solid forms of compound i or salts thereof
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013332A1 (fr) 1997-09-05 1999-03-18 Matsushita Electric Industrial Co., Ltd. Procede de polarisation de fluorescence
US6794158B2 (en) 2001-04-09 2004-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
EA012837B1 (ru) * 2004-06-30 2009-12-30 Янссен Фармацевтика Н.В. Производные хиназолинона в качестве ингибиторов parp
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008013838A2 (en) 2006-07-25 2008-01-31 Cephalon, Inc. Pyridizinone derivatives
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
SI2271626T1 (sl) * 2008-03-27 2015-03-31 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
NZ598262A (en) * 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
SG11202010183XA (en) 2018-04-30 2020-11-27 Ribon Therapeutics Inc Pyridazinones as parp7 inhibitors
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
AU2020375821A1 (en) 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors

Also Published As

Publication number Publication date
US10870641B2 (en) 2020-12-22
AR121419A1 (es) 2022-06-08
PH12020551760A1 (en) 2021-06-28
AU2024200566A1 (en) 2024-02-15
US10550105B2 (en) 2020-02-04
CY1126132T1 (el) 2023-11-15
IL278116A (en) 2020-11-30
EP3788040A1 (en) 2021-03-10
PL3788040T3 (pl) 2023-08-07
CL2020002821A1 (es) 2021-02-19
IL278116B2 (en) 2024-04-01
HRP20230458T1 (hr) 2023-07-21
US11566020B1 (en) 2023-01-31
HUE062096T2 (hu) 2023-09-28
CN112424188A (zh) 2021-02-26
LT3788040T (lt) 2023-06-26
JP2021523104A (ja) 2021-09-02
US20230192664A1 (en) 2023-06-22
IL278116B1 (en) 2023-12-01
WO2019212937A1 (en) 2019-11-07
MA52486B1 (fr) 2023-04-28
ECSP20069404A (es) 2021-01-29
MA52486A (fr) 2021-03-10
SG11202010183XA (en) 2020-11-27
TWI811353B (zh) 2023-08-11
EP4234551A2 (en) 2023-08-30
MD3788040T2 (ro) 2023-10-31
SI3788040T1 (sl) 2023-07-31
EA202092590A1 (ru) 2021-04-08
KR20210014108A (ko) 2021-02-08
US20190330194A1 (en) 2019-10-31
RS64283B1 (sr) 2023-07-31
AU2019262927B2 (en) 2023-11-02
US20210024502A1 (en) 2021-01-28
MX2023005804A (es) 2023-05-29
DK3788040T3 (da) 2023-05-08
PT3788040T (pt) 2023-07-12
MX2020011465A (es) 2020-12-07
JP2022017221A (ja) 2022-01-25
CO2020013599A2 (es) 2020-12-21
IL308983A (en) 2024-01-01
CR20200518A (es) 2021-03-22
BR112020022006A2 (pt) 2021-01-26
FI3788040T3 (fi) 2023-06-13
CA3098585A1 (en) 2019-11-07
EP4234551A3 (en) 2023-10-11
AU2019262927A1 (en) 2020-11-12
US20200123134A1 (en) 2020-04-23
US11014913B2 (en) 2021-05-25
ES2949538T3 (es) 2023-09-29
EP3788040B1 (en) 2023-04-12
TW202344505A (zh) 2023-11-16
JP6942896B2 (ja) 2021-09-29
TW202014416A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
PE20211382A1 (es) Piridazinonas como inhibidoras de parp7
PE20170331A1 (es) Derivados quinolina como inhibidores smo
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20190175A1 (es) Compuestos de pirrolotriazina como inhibidores de tam
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20210373A1 (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos
PE20060600A1 (es) Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa
PE20161476A1 (es) Derivados de indolin-2-ona o pirrolo-piridin-2-ona
ECSP088218A (es) Bencimidazoles sustituidos como inhibidores de cinasa
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
DOP2011000067A (es) Derivados de picolinamida como inhibidores de cinasa
BR112018001017A2 (pt) inibidores do receptor de fator-1 de estimulação de colônia (csf-1r)
AR059249A1 (es) Compuesto amina trisustituido
CR20140045A (es) Compuestos de n-tio-antranilamida y sus usos como plaguicidas
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
EA201100447A1 (ru) Органические соединения
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
PE20130152A1 (es) Derivados de heterociclo biciclicos como inhibidores de proteina quinasa b
AR061567A1 (es) Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos
ECSP056131A (es) Compuestos de carbonilo
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
CR20110605A (es) Compuestos heterocíclicos antivirales